• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全基因组分析指导晚期癌症患者治疗的成本及成本变化轨迹

The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

作者信息

Weymann Deirdre, Laskin Janessa, Roscoe Robyn, Schrader Kasmintan A, Chia Stephen, Yip Stephen, Cheung Winson Y, Gelmon Karen A, Karsan Aly, Renouf Daniel J, Marra Marco, Regier Dean A

机构信息

Canadian Centre for Applied Research in Cancer Control (ARCC)Cancer Control ResearchBC Cancer AgencyVancouverBritish ColumbiaCanada.

Division of Medical OncologyBC Cancer AgencyVancouverBritish ColumbiaCanada.

出版信息

Mol Genet Genomic Med. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. eCollection 2017 May.

DOI:10.1002/mgg3.281
PMID:28546995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5441418/
Abstract

BACKGROUND

Limited data exist on the real-world costs of applying whole-genome analysis (WGA) in a clinical setting. We estimated the costs of applying WGA to guide treatments for patients with advanced cancers and characterized how costs evolve over time.

METHODS

The setting is the British Columbia Cancer Agency Personalized OncoGenomics (POG) program in British Columbia, Canada. Cost data were obtained for patients who enrolled in the program from 2012 to 2015. We estimated mean WGA costs using bootstrapping. We applied time series analysis and produced 10-year forecasts to determine when costs are expected to reach critical thresholds.

RESULTS

The mean cost of WGA over the study period was CDN$34,886 per patient (95% CI: $34,051, $35,721). Over time, WGA costs decreased, driven by a reduction in costs of sequencing. Yet, costs of other components of WGA increased. Forecasting showed WGA costs may not reach critical thresholds within the next 10 years.

CONCLUSION

WGA costs decreased over the studied time horizon, but expenditures needed to realize WGA remain significant. Future research exploring costs and benefits of WGA-guided cancer care are crucial to guide health policy.

摘要

背景

关于在临床环境中应用全基因组分析(WGA)的实际成本的数据有限。我们估计了应用WGA指导晚期癌症患者治疗的成本,并描述了成本随时间的变化情况。

方法

研究背景为加拿大不列颠哥伦比亚省的不列颠哥伦比亚癌症机构个性化肿瘤基因组学(POG)项目。获取了2012年至2015年参与该项目患者的成本数据。我们使用自助法估计了WGA的平均成本。我们应用时间序列分析并进行了10年预测,以确定成本预计何时达到临界阈值。

结果

研究期间WGA的平均成本为每位患者34,886加元(95%置信区间:34,051加元,35,721加元)。随着时间的推移,WGA成本下降,这是由测序成本的降低推动的。然而,WGA其他组成部分的成本有所增加。预测显示,WGA成本在未来10年内可能不会达到临界阈值。

结论

在所研究的时间范围内,WGA成本有所下降,但实现WGA所需的支出仍然很高。未来探索WGA指导的癌症护理的成本和效益的研究对于指导卫生政策至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5558/5441418/e4dccfc0d387/MGG3-5-251-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5558/5441418/6156f826cf22/MGG3-5-251-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5558/5441418/e4dccfc0d387/MGG3-5-251-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5558/5441418/6156f826cf22/MGG3-5-251-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5558/5441418/e4dccfc0d387/MGG3-5-251-g002.jpg

相似文献

1
The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.全基因组分析指导晚期癌症患者治疗的成本及成本变化轨迹
Mol Genet Genomic Med. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. eCollection 2017 May.
2
Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care.基于研究的晚期癌症综合基因组测序用于癌症高级护理的早期经济分析。
J Community Genet. 2022 Oct;13(5):523-538. doi: 10.1007/s12687-021-00557-w. Epub 2021 Nov 29.
3
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.从全基因组分析在晚期癌症患者治疗中的应用中吸取的经验教训。
Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000570. doi: 10.1101/mcs.a000570.
4
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.二氢吡啶类钙通道阻滞剂参考定价的临床和经济后果。
Clin Pharmacol Ther. 2003 Oct;74(4):388-400. doi: 10.1016/S0009-9236(03)00227-3.
5
Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.帕利珠单抗预防早产儿在美国的成本效用:国家政策视角。
J Med Econ. 2012;15(5):987-96. doi: 10.3111/13696998.2012.690013. Epub 2012 May 10.
6
Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.美国医疗补助计划覆盖的早产儿人群中帕利珠单抗的成本效益分析。
J Med Econ. 2012;15(5):997-1018. doi: 10.3111/13696998.2012.672942. Epub 2012 Mar 21.
7
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.西妥昔单抗用于转移性结直肠癌的前瞻性成本效益分析:加拿大国立癌症研究所临床试验组CO.17试验评估
J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.
8
Family practice residents' awareness of medical care costs in British Columbia.不列颠哥伦比亚省家庭医学住院医师对医疗费用的认知
Fam Med. 2002 Feb;34(2):104-9.
9
The costs of change: direct medical costs of solid organ transplantation in British Columbia, Canada, 1995-2003.变革成本:1995-2003 年加拿大不列颠哥伦比亚省实体器官移植的直接医疗成本。
Value Health. 2009 Mar-Apr;12(2):282-92. doi: 10.1111/j.1524-4733.2008.00445.x. Epub 2008 Sep 9.
10
Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.北欧国家癌症筛查对截至2017年的死亡、成本和生活质量的影响。
Acta Oncol. 1997;36 Suppl 9:1-60.

引用本文的文献

1
The economic costs of precision medicine for clinical translational research among children with high-risk cancer.高危癌症儿童临床转化研究中精准医学的经济成本。
NPJ Precis Oncol. 2024 Oct 5;8(1):224. doi: 10.1038/s41698-024-00711-w.
2
Mass Spectrometry-Based Proteomics for Classification and Treatment Optimisation of Triple Negative Breast Cancer.基于质谱的蛋白质组学用于三阴性乳腺癌的分类和治疗优化
J Pers Med. 2024 Sep 5;14(9):944. doi: 10.3390/jpm14090944.
3
Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma.

本文引用的文献

1
A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder.自闭症谱系障碍临床基因组检测策略的微成本和成本后果分析。
Genet Med. 2017 Nov;19(11):1268-1275. doi: 10.1038/gim.2017.47. Epub 2017 May 4.
2
Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.非小细胞肺癌和黑色素瘤患者的下一代测序:成本和预算影响分析。
Ecancermedicalscience. 2016 Oct 28;10:684. doi: 10.3332/ecancer.2016.684. eCollection 2016.
3
A time-and-motion approach to micro-costing of high-throughput genomic assays.
循环肿瘤DNA:推动胰腺导管腺癌临床范式的演变
Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157651. doi: 10.1177/17588359231157651. eCollection 2023.
4
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation.迈向循环肿瘤DNA在转移性前列腺癌中的临床应用:整合的机遇与解读的陷阱
Front Oncol. 2022 Nov 10;12:1054497. doi: 10.3389/fonc.2022.1054497. eCollection 2022.
5
Genome screening, reporting, and genetic counseling for healthy populations.健康人群的基因组筛查、报告和遗传咨询。
Hum Genet. 2023 Feb;142(2):181-192. doi: 10.1007/s00439-022-02480-7. Epub 2022 Nov 4.
6
Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions.精准医学经济评估工具:评估基于异质性信息的决策价值框架的范围综述。
Pharmacoeconomics. 2022 Oct;40(10):931-941. doi: 10.1007/s40273-022-01176-0. Epub 2022 Jul 27.
7
Bioinformatic Analysis of Human Cumulus Cells to Unravel Cellular's Processes that Could Be Used to Establish Oocyte Quality Biomarkers with Clinical Application.人类卵丘细胞的生物信息学分析,以揭示可能用于建立具有临床应用的卵母细胞质量生物标志物的细胞过程。
Reprod Sci. 2023 Feb;30(2):642-655. doi: 10.1007/s43032-022-01046-2. Epub 2022 Jul 26.
8
Seq: A High-Performance Language for Bioinformatics.Seq:一种用于生物信息学的高性能语言。
Proc ACM Program Lang. 2019 Oct;3. doi: 10.1145/3360551. Epub 2019 Oct 10.
9
Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?与基因不稳定相关的分子改变是否值得作为生物标志物,用于指导或排除黑色素瘤患者接受免疫治疗?
Front Oncol. 2021 May 5;11:666624. doi: 10.3389/fonc.2021.666624. eCollection 2021.
10
A Primer on the Analysis of High-Throughput Sequencing Data for Detection of Plant Viruses.用于检测植物病毒的高通量测序数据分析入门
Microorganisms. 2021 Apr 14;9(4):841. doi: 10.3390/microorganisms9040841.
一种用于高通量基因组检测微观成本核算的时间与动作研究方法。
Curr Oncol. 2016 Oct;23(5):304-313. doi: 10.3747/co.23.2987. Epub 2016 Oct 25.
4
Cost analysis of whole genome sequencing in German clinical practice.德国临床实践中全基因组测序的成本分析
Eur J Health Econ. 2017 Jun;18(5):623-633. doi: 10.1007/s10198-016-0815-0. Epub 2016 Jul 5.
5
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.从全基因组分析在晚期癌症患者治疗中的应用中吸取的经验教训。
Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000570. doi: 10.1101/mcs.a000570.
6
Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis: A Report of the Association for Molecular Pathology.基因组测序程序微观成本分析与健康经济成本影响分析:分子病理学协会报告
J Mol Diagn. 2016 May;18(3):319-328. doi: 10.1016/j.jmoldx.2015.11.010. Epub 2016 Apr 13.
7
Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.全外显子组测序在智障儿童中的有效性及传统诊断流程的成本
Genet Med. 2016 Sep;18(9):949-56. doi: 10.1038/gim.2015.200. Epub 2016 Feb 4.
8
Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.癌症基因组图谱胶质母细胞瘤患者队列的多中心影像结果研究:总生存期和无进展生存期的影像预测因素
Neuro Oncol. 2015 Nov;17(11):1525-37. doi: 10.1093/neuonc/nov117. Epub 2015 Jul 22.
9
Big Data: Astronomical or Genomical?大数据:天文学的还是基因组学的?
PLoS Biol. 2015 Jul 7;13(7):e1002195. doi: 10.1371/journal.pbio.1002195. eCollection 2015 Jul.
10
Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.用于诊断结直肠癌和息肉病综合征的新一代测序面板:成本效益分析
J Clin Oncol. 2015 Jun 20;33(18):2084-91. doi: 10.1200/JCO.2014.59.3665. Epub 2015 May 4.